Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2018 ASH Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL
Dr. Gauthier on Potential for CAR T Cells in CLL
OncLive News Network On Location: In San Diego Monday, December 3
Oncology Conference Articles
Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL
The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.
Competition Grows in Anti-BCMA CAR Pipeline for Multiple Myeloma
A multitude of BCMA-targeted CAR T-cell therapies are currently in development, each demonstrating different efficacy and safety profiles and each with different constructs.
Mutation in BCL2 Protein Confers Resistance to Venetoclax
A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.
Daratumumab Plus Rd New Frontline Standard in Transplant-Ineligible Myeloma
The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.
Rivaroxaban May Reduce Blood Clot Risk During Active Systemic Cancer Therapy
Rivaroxaban may significantly reduce venous thromboembolism occurrence among patients actively being treated with systemic therapy, according to results from the phase IIIb CASSINI trial.
High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL
Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.
Ibrutinib/Rituximab Improves OS, PFS Versus FCR for Untreated CLL
The combination of ibrutinib and rituximab significantly improved overall survival and progression-free survival compared with standard fludarabine, cyclophosphamide, and rituximab for younger patients with chronic lymphocytic leukemia.
Selinexor Induces Responses in a Quarter of Patients with Heavily Pretreated MM
A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.
Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma
Axicabtagene ciloleucel elicited a 2-year overall survival rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve.
Quizartinib Update Presented as FDA Weighs AML Approval
The overall survival benefit with quizartinib in patients with relapsed/refractory
-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.
Phase III Data Showcase PFS Benefit With Frontline Ibrutinib/Obinutuzumab Combo in High-Risk CLL
The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Acalabrutinib Monotherapy Produces Durable Response in Mantle Cell Lymphoma
Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma shows that responses are durable with no new safety signals observed.
Lenalidomide/Rituximab Improves PFS in Indolent Non-Hodgkin Lymphoma
regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Antibody-Drug Conjugate Impresses in Relapsed/Refractory DLBCL
The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.
Venetoclax With HMAs Shows Promise in AML for Patients Ineligible for High-Dose Chemo
More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.
Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma
The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.
New Prediction Model Improves Personalized Insight Into MDS Survival
An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease.
Mosunetuzumab Shows Promise for Non-Hodgkin Lymphoma
The CD3 and CD20 bispecific antibody mosunetuzumab demonstrated promising complete remission rates with tolerable toxicity for patients with relapsed/refractory B-cell indolent and aggressive non-Hodgkin lymphoma.
Anti-PD-1 Plus Umbralisib/Ublituximab Hits 90% Response in CLL
The triplet regimen of pembrolizumab (Keytruda) plus umbralisib and ublituximab reached a 90% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.
Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis
Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.
Liso-Cel Demonstrates Durable Responses in Heavily Pretreated, High-Risk CLL
Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.
Ibrutinib Efficacy Sustained at 7-Year Analysis for CLL
Single-agent ibrutinib continued to demonstrate strong results after 7 years of follow-up in both the frontline and heavily pretreated, relapsed/refractory setting for patients with CLL and SLL.
Maintenance Ixazomib Extends PFS in Newly Diagnosed Multiple Myeloma
Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.
Ibrutinib/Venetoclax Combination Achieves High Rate of MRD Negativity in Relapsed/Refractory CLL
The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.
Zanubrutinib Highly Active in Relapsed/Refractory MCL
The investigational agent zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, is highly active in patients with relapsed/refractory mantle cell lymphoma.
Checkpoint Inhibition May Improve CAR T-Cell Persistence
Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.
Daratumumab Safe and Effective When Added to VRd in Newly Diagnosed MM
Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.
First HCT Following CAR T-Cell Therapy Reduces Risk for ALL Relapse
Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.
Ibrutinib/CAR T Cell Combo Active in CLL
Concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor T-cell therapy JCAR014 was well tolerated and led to an overall response rate of 83% in patients with relapsed or refractory chronic lymphocytic leukemia.
Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia
Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.
Reduced Treatment Equally Effective in DLBCL
Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.
Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up
Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.
Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL
Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.
Ibrutinib Established as Standard for Older CLL Patients
Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.
Myeloma Expert Previews 2018 ASH Abstracts
Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.
Key Takeaway 6: Role of Immunotherapy in R/R mHCC
Vogelzang Highlights Decades of Innovation in Prostate Cancer
Considering Oral Selinexor for Relapsed/Refractory Myeloma
MRD: A Key Predictor of Clinical Outcomes in Acute Lymphoblastic Leukemia
Frontline Treatment for EGFR+ NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.